Processa Pharmaceuticals, Inc. Operating Lease, Liability, Current
Processa Pharmaceuticals, Inc. (PCSA) had Operating Lease, Liability, Current of $21.83 thousand as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2025-08-07
- 2025-06-30: Operating Lease, Liability, Current $21.83K.
- 2025-03-31: Operating Lease, Liability, Current $44.59K.
- 2024-12-31: Operating Lease, Liability, Current $66.91K.
- 2024-09-30: Operating Lease, Liability, Current $88.78K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2025-06-30 | $21.83K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $44.59K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $66.91K 10-K · filed 2025-03-20 |
| 2024-09-30 | $88.78K 10-Q · filed 2024-10-30 |
| 2024-06-30 | $87.50K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $84.88K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $83.65K 10-K · filed 2024-03-29 |
| 2023-09-30 | $82.74K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $81.89K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $81.17K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $78.90K 10-K · filed 2024-03-29 |
| 2022-09-30 | $76.26K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $26.55K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $49.12K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $71.08K 10-K · filed 2023-03-30 |
| 2021-09-30 | $92.77K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $92.45K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $97.27K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $87.20K 10-K · filed 2022-03-30 |
| 2020-09-30 | $79.77K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $71.97K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $78.01K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $77.99K 10-K · filed 2021-03-25 |
| 2019-09-30 | $77.42K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $77.54K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $58.50K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |